Kang Jeehoon, Kim Tae-Won, Hur Jin, Kim Hyo-Soo
Department of Medicine, Seoul National University Hospital, Seoul, South Korea; Molecular Medicine & Biopharmaceutical Science, Graduate School of Convergence Science & Technology, Seoul National University, Seoul, South Korea.
Molecular Medicine & Biopharmaceutical Science, Graduate School of Convergence Science & Technology, Seoul National University, Seoul, South Korea; National Research Laboratory for Stem Cell Niche, Center for Medical Innovation, Seoul National University Hospital, Seoul, South Korea.
Front Cardiovasc Med. 2016 Nov 24;3:46. doi: 10.3389/fcvm.2016.00046. eCollection 2016.
Cell therapy in myocardial infarction (MI) is an innovative strategy that is regarded as a rescue therapy to repair the damaged myocardium and to promote neovascularization for the ischemic border zone. Among several stem cell sources for this purpose, autologous progenitors from bone marrow or peripheral blood would be the most feasible and safest cell-source. Despite the theoretical benefit of cell therapy, this method is not widely adopted in the actual clinical practice due to its low therapeutic efficacy. Various methods have been used to augment the efficacy of cell therapy in MI, such as using different source of progenitors, genetic manipulation of cells, or priming of the cells or hosts (patients) with agents. Among these methods, the strategy to augment the therapeutic efficacy of the autologous peripheral blood mononuclear cells (PBMCs) by priming agents may be the most feasible and the safest method that can be applied directly to the clinic. In this review, we will discuss the current status and future directions of priming PBMCs or patients, as for cell therapy of MI.
心肌梗死（MI）的细胞治疗是一种创新策略，被视为一种修复受损心肌并促进缺血边缘区新血管形成的挽救疗法。在用于此目的的几种干细胞来源中，来自骨髓或外周血的自体祖细胞将是最可行和最安全的细胞来源。尽管细胞治疗具有理论上的益处，但由于其治疗效果低，该方法在实际临床实践中并未得到广泛应用。已经使用了各种方法来提高MI中细胞治疗的疗效，例如使用不同来源的祖细胞、对细胞进行基因操作，或用药物对细胞或宿主（患者）进行预处理。在这些方法中，通过预处理剂提高自体外周血单个核细胞（PBMC）治疗效果的策略可能是最可行和最安全的方法，可直接应用于临床。在本综述中，我们将讨论预处理PBMC或患者在MI细胞治疗方面的现状和未来方向。
